Serious adverse events ( · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Intervention not reported
Adverse events Length of · and
It is very uncertain whether the intervention changes adverse events Length of (very low certainty).
1 finding from 1 review
Adverse events Length of · and
2 findings from 1 review
Adverse events Length of · and
1 finding from 1 review
Adverse events Length of · and
1 finding from 1 review
Adverse events Length of · and
1 finding from 1 review
Adverse events Length of · and
It is very uncertain whether summary of findings: General medication review changes adverse events Length of compared with usual care (very low certainty).
1 finding from 1 review
Adverse events (serious) · carpal tunnel syndrome
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events ( · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…
1 finding from 1 review
Adverse events: backache · patients undergoing lumbar punctures with atraumatic needles (Whitacre, Atraucan, Sprotte, Cappe‐Deutsh, Pajunk, Gertie Marx, Durasafe,…
Larger atraumatic needles probably leads to lower adverse events: backache compared with smaller atraumatic needles (moderate certainty).
1 finding from 1 review
Adverse events: backache · participants undergoing lumbar puncture
Traumatic needles showed no clear difference in adverse events: backache compared with atraumatic needles (moderate certainty).
1 finding from 1 review
Adverse events (overall) · adults undergoing arthroscopically assisted ACL reconstruction1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Adverse events incidence · patients with stable angina pectoris
It is very uncertain whether ranolazine (monotherapy) changes adverse events incidence compared with placebo (very low certainty).
1 finding from 1 review
Adverse events incidence · patients with stable angina pectoris
Ranolazine (add‐on therapy) probably leads to higher adverse events incidence compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at end of · patients with chronic obstructive pulmonary disease
Airway bypass stents showed no clear difference in adverse events at end of compared with control (moderate certainty).
1 finding from 1 review
Adverse events at end of · patients with chronic obstructive pulmonary disease
Endobronchial coils leads to higher adverse events at end of compared with control (high certainty).
1 finding from 1 review
Adverse events at end of · patients with chronic obstructive pulmonary disease
Endobronchial valves leads to higher adverse events at end of compared with control (high certainty).
1 finding from 1 review
Adverse events at end of · patients with chronic obstructive pulmonary disease
Intrabronchial valves leads to higher adverse events at end of compared with control (high certainty).
1 finding from 1 review